Nevirapine Levels and Fluconazole

This study has been completed.
Information provided by:
Bamrasnaradura Infectious Diseases Institute Identifier:
First received: March 30, 2006
Last updated: NA
Last verified: November 2005
History: No changes posted

Nevirapine (NVP)-based antiretroviral therapy (ART) has been commonly used in many developing countries due to its affordability and feasibility. Nonetheless, the potential drug-drug interaction between NVP and fluconazole (FLU) is a major concern. NVP can induce cytochrome P450 isoenzymes in the liver while FLU inhibit the activity of this enzyme. The recent report has demonstrated that fluconazole significantly raises plasma NVP levels and may cause serious hepatotoxicity. Conversely, NVP does not significantly influence the plasma level of FLU. However, there have not been enough data or any recommendations to adjust NVP dosage for the concurrent use of both drugs in order to avoid the adverse events. A previous study has demonstrated that genetic disposition may play a role in NVP hypersensitivity reactions. There is little data of safety and tolerability for concurrent use of NVP and FLU in Asian populations. We therefore conducted this prospective observational study to compare the trough plasma NVP levels and frequencies of adverse events among antiretroviral HIV-infected patients who did not receive FLU and received FLU in different dosages for cryptococcosis prophylaxis or treatment; and subsequently received NVP-based ART regimens.

Adverse Event

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Plasma Nevirapine Levels and Adverse Events Among HIV-Infected Patients Concurrently Receiving Nevirapine-Based Antiretroviral Therapy and Fluconazole

Further study details as provided by Bamrasnaradura Infectious Diseases Institute:


Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. HIV-infected patients >15 years of age,
  2. naïve to antiretroviral therapy,
  3. were initiated with a NVP-based ART regimen,
  4. used NVP 200-mg once-daily lead-in dose, prior to escalation to 200 mg twice daily.

Exclusion Criteria:

  1. creatinine level was higher than 2.0 mg/ml
  2. liver aminotransferase enzyme was higher than five times of upper normal limit
  3. receiving a medication that has drug-drug interactions with NVP or FLU
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00309582

Sponsors and Collaborators
Bamrasnaradura Infectious Diseases Institute
Principal Investigator: Weerawat Manosuthi, MD Bamrasnaradura Infectious Diseases Institute
  More Information

No publications provided Identifier: NCT00309582     History of Changes
Other Study ID Numbers: BIR2405
Study First Received: March 30, 2006
Last Updated: March 30, 2006
Health Authority: Thailand: Ministry of Public Health processed this record on March 30, 2015